Skip To Main Content
Betty Wang on Muck Rack

Betty Wang

As seen in: MSN, Yahoo Life, Nature, Wiley Online Library, Aol, Design and Make, Flipboard, The Epoch Times, The Diplomat Magazine, Dove Medical Press and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Betty

Contact Betty, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology

|
By Mohamad Watfa, Kristina Dortche, Gagan Fervaha, Salim K. Younis, Abdulrahman Muataz Al-Bayati, Betty Wang, Rui Bernardino, Jesse K. McKenney, Samuel Haywood, Rubén López Olivares, Riccardo Autorino, Jihad H. Kaouk, Christopher J. Weight, Zeyad R. Schwen, Jane Nguyen
| Nature Verified
Abstract Grade Group 1 (GG1) prostate cancer is biologically indolent and typically managed with active surveillance (AS), yet pT3a pathology is occasionally identified at radical prostatectomy (RP). Its prognostic significance in GG1 disease remains incompletely defined. Retrospective cohort of 40 patients with GG1 and pT3a disease on RP (2000–2022), confirmed on central pathologic re-review.
Open in Who Shared Issue with article?

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.

|
By Can Aydogdu, Betty Wang, Sean McSweeney
| UroToday Verified
To evaluate whether longitudinal tumour-informed circulating tumour DNA (ctDNA) testing identifies patients at increased risk of upstaging and recurrence in high-risk non-muscle-invasive bladder cancer (NMIBC). A cohort of 52 patients with high-risk NMIBC underwent serial plasma ctDNA testing using a personalised tumour-informed assay. The ctDNA was obtained at initial presentation and at approximately 3-month surveillance intervals during appropriate routine clinical NMIBC therapy and follow-up.
Open in Who Shared Issue with article?

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer

|
By Can Aydogdu, Glickman Urological, Betty Wang
| BJU International Journal Verified
AUC area under the curve ctDNA circulating tumour DNA CIS carcinoma in situ cT clinical T stage ctDNA circulating tumour DNA FGFR3 fibroblast growth factor receptor 3 HR hazard ratio (N)MIBC (non-)muscle-invasive bladder cancer OR odds ratio pT pathological T stage (N)(P)PV (negative) (positive) predictive value RC radical cystectomy TURBT transurethral resection of bladder tumour Introduction Non-muscle-invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder cancers and...
Open in Who Shared Issue with article?
See all 58 licensed articles (63 Total)